Catalyst ligands

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-95-9,4-Bromo-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

In a flame dried 50-mL 3-neck flask fitted with a condenser, a mixture of anthraceneboronic acid 35-7 (522 mg, 0.985 mmol), 4-bromo-2,2?-bipyridine (154 mg, 0.657 mmol), and cesium carbonate (640 mg, 1.97 mmol) in EtOH (15 mL) and water (2 mL) was degassed by refluxing under argon stream for 75 minutes. Then Pd(OAc)2 (29.7 mg, 0.131 mmol) and PPh3 (138 mg, 0.526 mmol) were added in one portion. Refluxing under argon was continued until the reaction was complete in 90 minutes. The reaction mixture was then allowed to cool to room temperature and filtered; the solid residue was rinsed with DCM and MeOH. The filtrate was concentrated in vacuo, and the resulting residue was purified by reversed-phase flash chromatography (C18 190 SiO2, eluted with gradient of 0.09% 58 HCl in 23 MeOH). The pure product was isolated by basification of combined and concentrated fractions with solid 43 NaHCO3 (200 mg) followed by extraction with DCM twice. The combined DCM layers were then dried over MgSO4 and concentrated in vacuo to yield 192 product as a yellow solid (316 mg, 50%).

14162-95-9, 14162-95-9 4-Bromo-2,2′-bipyridine 12087122, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Profusa, Inc.; GAMSEY, Soya; BERNAT, Viachaslau; KUTYAVIN, Alex; CLARY, Jacob William; PRADHAN, Sulolit; (192 pag.)US2018/179233; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3779-42-8, 3-Bromo-N,N,N-trimethylpropan-1-aminium bromide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a vigorously-stirred suspension of Compound 5 (80 mg, 0.14 mmol) and K2CO3 (230 mg, 1.7 mmol) in DMF (30 mL) is added (1- bromopropyl) -trimethylammonium bromide (0.3 g, 16.6 mmol) at 50 C. The mixture is stirred at this temperature for 18 h. After removal of the DMF under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and filtered through a pad of silica gel (depth 2 cm) supported on a steel frit (diameter 3.5 cm). After washing the pad with methanol (ca. 1L) the crude product is eluted with acetic acid: methanol: water (3: 2: 1, by vol. ). Appropriate fractions are collected and, after evaporation of the solvent under reduced pressure, the residue obtained is purified by chromatography on a column (2.5 x 40 cm) of Sephadex LH-20 eluting with n-butanol: water: acetic acid (5: 4: 1, by vol., upper phase). After removal of the solvent from appropriate fractions under reduced pressure, the residue obtained is dissolved in methanol (5 mL) and the solution is passed through a short column (3.5 x 20 cm) of anion exchange resin (Amberlite IRA 400, chloride form). After collection of the eluate, solvent is removed under reduced pressure and the residue obtained is dried under high vacuum to yield the dichloride salt as violet crystals. 1H-NMR : 6H (300MZ, CD30D) : 0.75 (T, 3J7. 5 Hz, 3 H), 1.05-1. 20 (m, 14 H), 1.45- 1.50 (m, 2 H), 2.05-2. 15 (m, 4 H), 2.15-2. 20 (m, 2 H), 2.95 (s, 18 H), 3.35-3. 45 (m, 4 H), 3.95 (T, 3J7. 5 Hz, 4 H), 4.55 (t, 3J7. 5 Hz, 2 H), 6. 85 (m, 1 H), 7.35 (m, 2 H), 8.85-8. 90,9. 15-9.20, (3 X M, 8 H), 10.10 (s, 2 H).

3779-42-8, The synthetic route of 3779-42-8 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; DESTINY PHARMA LIMITED; SOLVIAS AG; WO2004/56828; (2004); A2;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.

[00134] To a solution of 4-(pyren-1 -yl)butanal (37 mg, 0.14 mmol) in 0.9 ml_ DCE, Boc3Cyclam (45 mg, 0.09 mmol) was added and stirred together with 4A molecular sieves for 2 h under nitrogen atmosphere. To this solution sodium triacetoxyborohydride (38 mg, 0.18 mmol) was added and the reaction mixture was allowed to stir at ambient temperature over 24 h under nitrogen atmosphere. Subsequently, the reaction mixture was diluted with sodium bicarbonate and extracted with DCM. The extract was purified by flash chromatography with 35% ethyl acetate/hexanes to give the product (43 mg, 63%); 1 H NMR (400 MHz, CDCb) delta 8.29 (d, J = 9.3 Hz, 1H), 8.21 – 7.98 (m, 7H), 7.88 (d, J = 7.8 Hz, 1H), 3.46 – 3.09 (m, 14H), 2.59 (s, 2H), 2.50 – 2.33 (m, 4H), 1.93 – 1.74 (m, 4H), 1.73 – 1.58 (m, 4H), 1.53 – 1.41 (m, 27H); 13C NMR (100 MHz, CDCb) delta 155.69, 136.80, 131.44, 130.91, 129.80, 128.58, 127.52, 127.24, 127.20, 126.57, 125.81, 125.1 1, 125.05, 124.86, 124.81, 124.67, 123.40, 79.55, 79.36, 55.42, 48.69, 48.55, 47.30, 46.90, 46.62, 45.69, 33.54, 29.85, 29.72, 28.56, 28.50, 26.79; LRMS (ESI+) m/z calc’d for CHesN- e [M + H]+ 757.49, found 757.69., 170161-27-0

As the paragraph descriping shows that 170161-27-0 is playing an increasingly important role.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; KRASKOUSKAYA, Dziyana; CABRAL, Aaron; MURCAR-EVANS, Bronte; TOUTAH, Krimo; DE ARAUJO, Elvin; (141 pag.)WO2019/68177; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.

General procedure: The phase-transfer catalysts (C1-C11) were synthesized according to the proceduresbelow. To a solution of cinchonidine (1.00 g, 3.4 mmol) in THF (50 mL) was addedthe aryl benzyl bromides (3.4 mmol). The mixture was heated for 6-8 h at reflux.After cooling to room temperature, the mixture was poured into MTBE (150 mL)under stirring. The precipitated solid was filtrated and recrystallized fromCH3OH/MTBE to afford C1-C11, 485-71-2

485-71-2 Cinchonidine 101744, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Li, Ruipeng; Liu, Zhenren; Chen, Liang; Pan, Jing; Zhou, Weicheng; Beilstein Journal of Organic Chemistry; vol. 14; (2018); p. 1421 – 1427;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

3922-40-5, 1,10-Phenanthroline-4,7-diol is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To the reaction flask by adding 4.2 g (0.02mol) 4,7-dihydroxy -1,10-phenanthroline, 3.4 g (0.02mol) copper chloride dihydrate, 20 ml anhydrous acetic acid, 5 ml water, heating reflux for 10 hours, still, to separate out the solid, the solid drying cocatalyst 4.0 g., 3922-40-5

3922-40-5 1,10-Phenanthroline-4,7-diol 77524, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Zhengzhou University; Li, RuiJun; Li, xueyang; Li, CaiJuan; Li, Jie; Yang, GuanYu; (8 pag.)CN104151133; (2016); B;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.485-71-2,Cinchonidine,as a common compound, the synthetic route is as follows.,485-71-2

General procedure: A mixture of (-)-cinchonidine (1.0 mmol) and benzyl bromide 3 (1.0 mmol) having sulfonamidegroup was stirred in DMF (4 mL) at 25 C for 20 h. After the reaction was completed, the reaction mixture was added dropwise to ether (50mL) with stirring. The solid precipitated was filtered,washed with ether (20 mL) and hexane (20 mL) to afford cinchonidinium salt 5

The synthetic route of 485-71-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Itsuno, Shinichi; Yamamoto, Shunya; Takata, Shohei; Tetrahedron Letters; vol. 55; 44; (2014); p. 6117 – 6120;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

1126-58-5, 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a magnetically stirred solution of substituted isatin (5mmol) in 7ml of absolute ethanol, a corresponding pyridinium acetohydrazide (5mmol) and three drops of trifluoroacetic acid were successively added. The reaction mixture was heated under reflux for 3h. After spontaneously cooling the solution to room temperature, the precipitate formed was filtered, washed with absolute ether and dried in vacuo.

1126-58-5, 1126-58-5 1-(2-Hydrazinyl-2-oxoethyl)pyridin-1-ium chloride 70773, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Bogdanov, Andrei V.; Zaripova, Ilyuza F.; Voloshina, Alexandra D.; Sapunova, Anastasia S.; Kulik, Natalia V.; Tsivunina, Irina V.; Dobrynin, Alexey B.; Mironov, Vladimir F.; Journal of Fluorine Chemistry; vol. 227; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.56100-20-0,5-Methyl-2,2′-bipyridine,as a common compound, the synthetic route is as follows.,56100-20-0

To a mixture of dry diisopropylamine (1.0 mL, 7.1 mmol) and dry THF (50 mL) was added dropwise n-butyllithium (1.6 M hexane solution, 3.8 mL, 6.1 mmol) at -78 C under a nitrogen atmosphere. The solution was stirred for 30 min and 6 (681 mg, 4.00 mmol) in dry THF (15 mL) was added at -78 C. The solution was stirred for 1 h and 1,4-dibromobutane (4.32 g, 20.0mmol) in dry THF (15 mL) was added. The solution was allowed to warm up to room temperature and stirred overnight. The reaction mixture was washed with aqueous sodium hydrogen carbonate and brine. The solution was dried over sodium sulfate and the solvent was removed under reduced pressure. The residue was separated by column chromatography on aluminium oxide (hexane/dichloromethane = 3/1 (v/v)) to give 7 as a white solid (964 mg, 79%). 7: mp 31 C; 1H NMR (300 MHz,CDCl3): 8.67 (d, 1H, J = 4.8 Hz), 8.51 (d, 1H, J = 2.1 Hz), 8.36 (d, 1H, J = 8.0 Hz), 8.31 (d, 1H, J = 8.1 Hz), 7.81 (td,1H, J = 7.7, 1.6 Hz), 7.64 (dd, 1H, J = 8.1, 2.0 Hz), 7.31-7.29 (m, 1H), 3.41 (t, 2H, J = 6.7 Hz), 2.70 (t, 2H, J = 7.6 Hz), 1.91 (quintet, 2H, J = 7.1 Hz), 1.70 (quintet, 2H, J = 7.6 Hz), 1.57-1.49 (m, 2H); 13C NMR (75 MHz, CDCl3): 156.2, 154.0,149.3, 149.2, 137.7, 136.9, 136.8, 123.5, 120.8, 120.7, 33.6,32.7, 32.5, 30.2, 27.7; MS (EI+): m/z 304 [M+]; IR (KBr,cm-1): 3067(m), 3053(m), 3011(m), 2962(m), 2943(s), 2928(s), 2866(s), 1585(s), 1574(m), 1557(s), 1460(s), 1429(s), 1392(m), 1350(w), 1304(w), 1258(m), 1230(m), 1205(m), 1190(w), 1148(w), 1092(w), 1065(w), 1042(w), 1030(m), 1013(m), 991(m), 860(s), 808(m), 785(s), 752(s), 737(m), 727(m), 640(s), 606(s); HRMS (EI+): m/z calcd for C15H1779BrN2 [M+]: 304.0575; found: 304.0577.

56100-20-0 5-Methyl-2,2′-bipyridine 11073848, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Ninomiya, Yoshikazu; Kozaki, Masatoshi; Suzuki, Shuichi; Okada, Keiji; Bulletin of the Chemical Society of Japan; vol. 87; 11; (2014); p. 1195 – 1201;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

170161-27-0, Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A mixture of PKS8179 (85 mg, 188 mol) and triBoc-cyclam (94 mg, 188 mol) in DCM (4 mL)was stirred at ambient temperature for 2 h and then sodium triacetoxyborohydride (120 mg, 564 mol)was added. The resulting mixture was stirred at ambient temperature overnight. Excess reagent wasquenched with aqueous NaHCO3, the layers were separated and the aqueous layer was extracted withdichloromethane. The combined organic layers were dried over anhydrous sodium sulfate andevaporated, and the crude residue was purified by Combi-Flash (silica gel; ethyl acetate in hexane) togive PKS8181 (140 mg, 80%) as a colorless gum which turned into a fluffy solid under vacuum., 170161-27-0

170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

Solid 1,3,5-triazacyclononane (16 mg, 0.12 mmol) was added to an aqueous solution of freshly prepared [Cp*Ir(H2O)3]SO4 (0.1 mmol in 5 mL). The yellow solution was stirred for 16 hours at room temperature and then taken to dryness under reduced pressure. The solid residue was taken up in 2 mL of dry methanol and the solution filtered through 0.2 mum pore size Teflon filter. Addition of 12 mL Et2O caused precipitation of a fine solid, and after taking off the pale yellow supernatant a colorless powder remained which was dried in vacuo. Yield 43 mg (78%). 1H-NMR (400 MHz, D2O): delta=3.09 (m, 6H), 2.95 (m, 6H), 1.81 (s, 15H). 13C-NMR (126 MHz, D2O): delta=88.1, 52.2, 7.8.

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Sheehan, Stafford Wheeler; Hintermair, Ulrich; Thomsen, Julianne M.; Brudvig, Gary W.; Crabtree, Robert H.; US2015/21194; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI